Ribomic Inc. (TYO:4591)
Japan · Delayed Price · Currency is JPY 82.00
-1.00 (-1.20%)
At close: Feb 6, 2026
Ribomic Revenue
In the fiscal year ending March 31, 2025, Ribomic had annual revenue of 2.00M JPY.
Revenue
2.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
4.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 2.00M | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | 65.00M | -15.00M | -18.75% |
| Mar 31, 2022 | 80.00M | -11.00M | -12.09% |
| Mar 31, 2021 | 91.00M | -30.00M | -24.79% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 12.92B |
| Linical | 9.87B |
| Kohjin Bio | 5.20B |
| Soiken Holdings | 4.87B |
| PRISM BioLab Co.,LTD | 677.33M |
| Carna Biosciences | 544.45M |
| D. Western Therapeutics Institute | 419.76M |
| Noile-Immune Biotech | 7.00M |